Many clinicians use sodium-glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase-4 inhibitors (DPP-4i) in patients with DM as a second-line therapy in combination with metformin (MET) monotherapy. This evidence concerns the gene DPP4 and diabetes mellitus.